Go beyond routine care1 More info with
a personalized path for heart
disease prevention2 More info.
Genetic testing can help you learn more about genetic heart risks that may impact you and your family.
- authorized
- Personalizedrecommendations.
- Privacy and protectionof your data.
Year
Genetic testing can offer preventive action.
personalized health insights forUnderstanding the facts
about heart health.
- It’s not always as obviousas you think.~50%of adults over 40 may have hidden heart 6 More infodisease.
- Early action leads to ahealthier heart.80%of cardiovascular disease is 7 More infopreventable.
- Make more informeddecisions about your care.#1Heart disease is the leading cause of 8 More infodeath in the United States.
We have three types of genetic reports to help you understand how your DNA could impact your heart.
- Genetic Health Risk Reports*Learn about Considerations and Limitations for Health Predispositions Reports, Carrier Status Reports and Genetic Health RisksRare genetic variants that lead to high risk for heart attack, heart failure, and stroke.
- Polygenic Risk Scores*Learn about Considerations and Limitations for Health Predispositions Reports, Carrier Status Reports and Genetic Health RisksCombinations of common genetic variants that impact the chances of developing heart-related conditions and traits.
- Pharmacogenetics Reports**Learn about Considerations and Limitations for Pharmacogenetics ReportsGenetic variants that impact how your body may process certain heart-related medications.
Genetic information for heart-related
conditions and traits.
Also included in your 23andMe+ Premium membership.
- Familial Hypercholesterolemia
- Hereditary Amyloidosis (TTR-Related)
- Atrial fibrillation
- Coronary Artery Disease
- High Blood Pressure
- Type 2 Diabetes
- LDL Cholesterol
- HDL Cholesterol
- Triglyceride
- Genetic Weight
- Saturated Fat and Weight
- SLCO1B1 Drug Transport
- CYP2C19 Drug Metabolism
Tools for preventive action and better health over time.
Also included in your 23andMe+ Premium membership.
Health TracksSM
The Health Tracks feature allows you to better understand how genetics and lifestyle can impact your likelihood of developing high blood pressure, coronary artery disease and type 2 diabetes over time.
Health Action Plan
Your Health Action Plan allows you to opt in and receive personalized recommendations based on genetic and non-genetic data.
Family Health History Tree
Opt in to easily input, track and download your family health history to share with your healthcare provider.
Blood testing
Eligible members may undergo add-on blood testing ordered by a clinician and offered at a convenient, third-party patient service center, and view their results in the 23andMe app.
A healthy heart is just the start.
You’ll also receive 190+ reports with new insights and features added throughout the year.
- BRCA1/BRCA2 (Selected Variants) Genetic Health Risk ReportOpt in to view your report results.
- Hereditary Prostate Cancer (HOXB13-Related) Genetic Health Risk ReportOpt in to view your report results.
- MUTYH-Associated Polyposis Genetic Health Risk ReportOpt in to view your report results.
- Breast Cancer (Powered by 23andMe Research) (available for females only)Opt in to view your report results.
- Prostate Cancer (Powered by 23andMe Research) (available for males only)Opt in to view your report results.
- Colorectal Cancer (Powered by 23andMe Research)Opt in to view your report results.
- Skin Cancer (Basal and Squamous Cell Carcinomas) (Powered by 23andMe Research)
- Skin Cancer (Melanoma) (Powered by 23andMe Research)
- Pharmacogenetics Reports
- DPYD Drug Metabolism
- Topic Pages
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Type 2 Diabetes (Powered by 23andMe Research)
- Gestational Diabetes (Powered by 23andMe Research) (available for females only)
- High Blood Pressure (Powered by 23andMe Research)
- HDL Cholesterol (Powered by 23andMe Research)
- Triglycerides (Powered by 23andMe Research)
- Wellness Reports
- Genetic Weight
- Saturated Fat and Weight
- Late-Onset Alzheimer’s Disease Genetic Health Risk ReportOpt in to view your report results.
- Related Condition: Parkinson’s Disease Genetic Health Risk Report
- Depression (Powered by 23andMe Research)
- Anxiety (Powered by 23andMe Research)
- Panic Attacks (Powered by 23andMe Research)
- ADHD (Powered by 23andMe Research)
- Sleep Health Matters to Mental Health
- Insomnia (Powered by 23andMe Research)
- Obstructive Sleep Apnea (Powered by 23andMe Research)
- Restless Legs Syndrome (Powered by 23andMe Research)
- Wellness and Trait Reports
- Deep Sleep
- Sleep Movement
- Wake-Up Time
- Historical MatchesSM feature
- Advanced DNA Relative filters
- Access to up to 5000 DNA relatives
Let’s get you heart smart.
Add to cartImportant test infoFrequently asked questions
- What’s included in 23andMe+ Premium?
- The 23andMeplus Premium is an annual membership and includes everything from our Health plus Ancestry Service plus access to exclusive reports and features that can help you learn more about your heart health, how you process certain medications**Learn about Considerations and Limitations for Pharmacogenetics Reports, likelihood for having migraine, and more. You’ll also receive enhanced ancestry features. Together, these 23andMe reports and features provide a more in-depth dive into your health and ancestry.
- How much does it cost to join 23andMe+ Premium?
- A 23andMeplus Premium membership costs original price: $268 sale price: $129 for new customers (original price: $199 sale price: $60 for kit plus $69 for membership). Existing Ancestry Service customers can upgrade here. Existing Health + Ancestry customers can upgrade here. Membership for new and existing customers renews automatically at $69peryr.
- Can you cancel the 23andMe+ Premium?
- You can cancel your annual 23andMeplus Premium at any time from within your 23andMe Account Settings. Read more about canceling your membership here: https://www.23andme.com/about/tos/subscription/
- Is there a monthly fee for 23andMe?
- We offer two base DNA kits, Ancestry Service and Health plus Ancestry, which are a one-time fee. We also have an optional add-on to the Health plus Ancestry kit, 23andMeplus Premium, which is our annual membership service that offers exclusive access to new premium reports and features throughout the year.
3 Headline: High Blood Pressure–Understanding the Silent Killer
Link: https://www.fda.gov/drugs/special-features/high-blood-pressure-understanding-silent-killer
Source: U.S Food and Drug Administration
4 Headline: Familial Hypercholesterolemia
Link: https://familyheart.org/familial-hypercholesterolemia
Source: Family Heart Foundation
5 Headline: Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users
Link: https://pubmed.ncbi.nlm.nih.gov/22658145/
Source: National Library of Medicine
6 Headline: 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association
Link: https://pubmed.ncbi.nlm.nih.gov/38264914/
Source: National Library of Medicine/American Heart Association with the National Institutes of Health
7 Headline: Nearly half of all adult Americans have cardiovascular disease
Link: https://www.sciencedaily.com/releases/2019/01/190131084238.htm
Source: Science Daily / American Heart Association
8 Headline: Heart Disease Facts
Link: https://www.cdc.gov/heart-disease/data-research/facts-stats/?CDC_AAref_Val=https://www.cdc.gov/heartdisease/facts.htm
Source: Centers for Disease Control and Prevention
*The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and PRS reports which are based on a genetic model that includes data and insights from 23andMe consented research participants, and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. Each PRS report describes if a person has a certain likelihood of developing a condition, but does not describe a person’s overall likelihood. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of 44 variants in the BRCA1 and BRCA2 genes. The report describes if a person's genetic result is associated with an increased risk of developing breast cancer and ovarian cancer and may be associated with an increased risk for prostate cancer, pancreatic cancer, and potentially other cancers. The variants included in this report do not represent the majority of the BRCA1/BRCA2 variants in people of most ethnicities. The MUTYH-Associated Polyposis Genetic Health Risk Report is indicated for reporting the Y179C and G396D variants in the MUTYH gene and an increased risk for colorectal cancer. The two variants included in this report are most common in people of Northern European descent. The Hereditary Prostate Cancer (HOXB13-Related) Genetic Health Risk report is indicated for reporting the G84E variant in the HOXB13 gene. The report describes if a person has the G84E variant and if a male is at increased risk for prostate cancer. The variant included in this report is most common in people of European descent, especially in people of Northern European descent. These reports do not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. These reports are for over-the-counter use by adults, and provide genetic information to inform discussions with a healthcare professional. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. For important information and limitations regarding genetic health risk reports, visit 23andme.com/test-info/.
**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Our SLCO1B1 Pharmacogenetics report provides certain information about variants associated with the processing of some therapeutics and provides interpretive drug information regarding the potential effect of simvastatin therapy. Our DPYD Pharmacogenetics report does not describe the association between detected variants and any specific therapeutic. Results for DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetic reports, visit 23andme.com/test-info/pharmacogenetics/